Phase I-II clinical trial with mitoclomine (NSC-114575) in chronic lymphocytic leukemia.
D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C012444:mitoclomine; D015057:1-Naphthylamine